Category: Clinical Trials
- ALK Experts
- ALK International
- ALK Positive News
- Clinical Trials
- Government
- Living with ALK+
- Nutrition
- Patient & Care Partner Stories
- Powered By Patients
- Recipes
- Research
-
Unlocking Hope: Breakthroughs in ALK-Positive Cancer Research for All Ages
The spectrum of ALK-positive cancer knows no age limits. Meet the faces of courage: the ordinary individuals with the ALK-positive mutation. This mutation, notorious for lung cancer in adults, defies
-
Oncolytic Virus Research Collaboration: Memgen Inc., UMichigan, and ALK Positive Inc.
The ALK Positive NSCLC Research Acceleration Committee (RAC) systematically reaches out to selected biotech companies with NSCLC treatments in development and/or trial. In February of 2022, RAC member Ray Hall
-
The ALK Positive Lung Cancer Registry and Survey Need You!!
What do patients that go only a short time before tumor progression have in common? What do patients that have many years before tumor progression have in common? What do
-
You Can Find a Clinical Trial with the Help of ALK Positive Inc.
At any juncture in treatment, those with ALK Positive cancers are faced with hard choices. Whether you are first starting treatment or you are changing treatment due to progression or
-
The New ALK Inhibitor: NVL-655 Trial Expands to Europe!
Who is this trial for: NVL-655 is a 4th generation, brain-penetrant, ALK TKI inhibitor created to overcome several limitations observed with currently available therapies. NVL-655 is designed to have activity in tumors that have developed resistance to first, second, and third-generation ALK inhibitors, including tumors with the solvent front G1202R mutation or compound mutations G1202R/L1196M…
-
The New ALK Inhibitor: NVL-655 Expands Clinical Trial Sites
Who is this trial for: NVL-655 is a 4th generation, brain-penetrant, ALK TKI inhibitor created to overcome several limitations observed with currently available therapies. NVL-655 is designed to have activity in tumors that have developed resistance to first, second, and third-generation ALK inhibitors, including tumors with the solvent front G1202R mutation or compound mutations G1202R/L1196M…
-
Pre-Clinical Research Sets the Stage for Clinical Trials
Clinical trials are studies that are done in humans to test a new treatment. Long before a clinical trial, a host of “pre-clinical” studies must test the feasibility, safety, and
-
Phase 1 Clinical Trial NCT05346494 by Imugene Limited
VAXINIA study of CF33-hNIS, an oncolytic virus, as monotherapy or in combination with Pembrolizumab, in adults with metastatic or advanced solid tumors (MAST), including NSCLC: Check ClinicalTrials.gov Imugene’s CF33, or
-
A New Clinical Trial in Italy: Does Supervised Exercise Improve Outcomes in Oncogene Addicted Lung Cancer?
For those diagnosed with advanced lung cancer, there is often the question of how lifestyle changes can improve the prognosis. A unique study in Italy called EXcellenT will measure how
-
ALKOVE Clinical Trial: a 4th Generation TKI from Nuvalent
The Phase 1/2 trial of Nuvalent, Inc.’s NVL-655, the fourth generation ALK TKI, has begun at Sarah Cannon Research Institute in Nashville, soon to be followed by additional locations. Below
-
An Exciting New Clinical Trial for Those who Are Resistant to ALK Inhibitors Is Recruiting Soon
Those in the ALK community fear the day when progression occurs after Lorlatinib, the “last” ALK inhibitor available. Although there are effective treatments after Lorlatinib, there is no standard treatment.
-
What is YAP and its significance for ALK-positive cancer
In recent years, a signal pathway called HIPPO, which is important in angiogenesis (blood vessel growth), has become important for the ALK cancer realm. There has been accumulating evidence that